Introduction
Prostate cancer is the most common cancer and the second leading cause of cancer-related deaths in men in the United States. 1 It is estimated that 186 320 new cases of prostate cancer were diagnosed in 2008 alone. Therapeutic options for patients with prostate cancer include radiotherapy, hormonal therapy, surgical therapy and treatment with cytotoxic chemotherapeutic agents. Despite a palliative benefit, these approaches do not engender a long-term beneficial effect on the overall survival of patients. Patients with late-stage prostate cancer may benefit from hormone therapy, which removes a primary factor mediating tumor growth, that is, male hormones (androgens). 2, 3 Unfortunately, after a few years, most patients become nonresponsive to this treatment, thus resulting in uncontrolled disease and patient death. In these contexts, there is a dire need to develop more effective therapeutic approaches to treat patients with end-stage prostate cancer, and genetic therapies represent promising approaches for the treatment of this neoplasm. 4 Adenovirus (Ad) is the most common delivery vehicle used for gene therapy. The most frequently used serotype of Ad for gene therapy has been recombinant forms of the type 5 Ad (Ad.5). Ad.5 uses the Coxsackie and adenovirus receptor (CAR) for infective entry into cells. 5 In many tumor types, for example, malignant glioma, ovarian cancer, prostate cancer, and particularly when examined in primary tumor specimens, the expression of CAR is reduced or absent in tumor cells compared with the surrounding nontumor tissue. Reduced CAR expression precludes efficient transduction of cancer cells by Ad. 5. 6,7 This finding may in part explain why gene therapy approaches using Ad. 5 have not been as successful as studies conducted in vitro using established cell lines. CAR is expressed in established cell lines that contain higher levels of CAR than observed in primary tumors in patients. An approach to circumvent the low efficiency of Ad.5 infection of tumor cells involves 'tropism modification' in which virus capsid proteins that normally associate with CAR are modified, permitting CAR-independent infectivity of tumor cells. Studies using various tumor cell types have shown that inclusion of the infective type 3 Ad sequence within the Ad type 5 virus knob (Ad.5/3 recombinant virus) promotes viral infectivity in tumor cells showing reduced or no CAR expression. 8, 9 It should be noted that Ad.5/3 also infects high CAR-expressing tumor cells with equal efficacy when compared with Ad.5, thereby providing an expanded scope of utility for Ad.5/3, in both low-and high-CAR-expressing tumor cells.
Melanoma differentiation-associated gene-7/interleukin-24 (mda-7/IL-24) was isolated by subtraction hybridization from human melanoma cells induced to undergo terminal differentiation by treatment with fibroblast interferon and mezerein. 10, 11 This novel tumor suppressor cytokine is a member of the IL-10 gene family. [12] [13] [14] [15] [16] [17] Forced expression of mda-7/IL-24, using Ad.5 (Ad.5-mda-7), inhibits growth and kills a broad spectrum of established cancer cell lines in vitro, without exerting injurious effects in multiple types of normal human epithelial cells, fibroblasts, melanocytes or astrocytes. [16] [17] [18] [19] [20] [21] Considering its robust cancer-specific apoptosis-inducing ability (by inducing endoplasmic reticulum stress) and tumor growth-suppressing properties in nude mice human tumor xenograft models, Ad.mda-7 (INGN 241) was evaluated in a phase I clinical trial in patients with advanced cancers. The results obtained from this trial demonstrate both safety and clinical efficacy. 22 In addition to its direct apoptosis-inducing properties, Ad.mda-7 also shows antiangiogenic, immunostimulatory and potent 'bystander' antitumor activities. 23, 24 These exciting results provide direct support for using mda-7/ IL-24 in developing an effective gene-based therapy for cancer.
This study explored the efficacy of a tropism-modified Ad-based cancer gene therapy approach for eradicating low CAR prostate cancer cells. We show that in low CAR human prostate cancer cells (PC-3), a recombinant Ad.5/3 virus delivering mda-7/IL-24 (Ad.5/3-mda-7) is more efficient than Ad.5 delivering mda-7 (Ad.5-mda-7) in infecting tumor cells, expressing MDA-7/IL-24 protein, inducing cancer-specific apoptosis, inhibiting in vivo tumor growth and exerting an antitumor 'bystander' effect in a nude mouse human prostate cancer xenograft model. On the basis of these considerations, Ad.5/3-mda-7 might represent an improved and more effective approach for delivering mda-7/IL-24, thereby improving its cancer therapeutic properties in prostate and other cancers.
Materials and methods
Cell lines, culture conditions and viability assays DU-145 and PC-3 prostate cancer cells were obtained from the American Type Culture Collection (Manassas, VA) and cultured as described previously. 25 The P69 cells are normal human prostate epithelial cells immortalized by the SV40 T/t antigen and are cultured as described previously. 25 Cell viability was determined by standard MTT (3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays. 25 Construction of Ad.5/3-mda-7 The genome of Ad.5/3-mda-7 ( Figure 1a ) was generated by homologous DNA recombination in Escherichia coli between linearized plasmid pShCMV.mda-7 and BstBIdigested genomic DNA of Ad.5/3-Luc1 vector. The resultant pAd.5/3-mda-7 plasmid was selected within. This plasmid, containing the Ad.5 genome encoding the mda-7/ IL-24 gene under control of the CMV (cytomegalovirus) promoter in place of the early viral E1 region and the recombinant F5/3 fiber gene, was selected with kanamycin (Knr). The Ad.5/3-mda-7 vector was rescued by transfecting 293 cells with pAd.5/3-mda-7 plasmid DNA cleaved with PacI to release the viral inverted terminal repeats.
Annexin V binding, trypan blue and caspase activity assays Annexin V binding assay was performed as described previously. 26 Caspase 3/7 activities were measured using the Caspases-Glo 3/7 Assay Kit (Promega, Madison, MI) according to the manufacturer's instructions. For trypan blue cell death assay, cells were harvested by treatment with 0.05% trypsin/0.53 mM EDTA (ethylenediaminetetraacetic acid). Cells were centrifuged at 200 Â g for 5 min to remove trypsin/EDTA. After the cell pellets were resuspended in 100 ml of phosphate-buffered saline (PBS), 100 ml of 0.4% trypan blue solution was added and mixed. Trypan blue cell suspension was left at room temperature for 10 min before the cells were counted using a hemocytometer. Cell death is defined as the percentage of the stained dead cells in the whole-cell population. Each experiment was repeated three times.
Detection of CARs on the cell surface Quantification of the surface expression of CAR was performed as described previously. 26 Briefly, cells were incubated with mouse monoclonal anti-CAR antibody for 1 h at 37 1C (1:1000 dilution; Millipore, Billerica, MA), washed, exposed to fluorescein isothiocyanate-conjugated anti-mouse immunoglobulins (1:1000 dilution; Sigma, St Louis, MO) for 1 h at 37 1C in the dark, washed again and analyzed on a FACSCalibur using CellQuest Pro version 5.2 (BD Biosciences, San Jose, CA). Unstained cells, cells stained with secondary antibody only and cells incubated with isotype control primary antibody, followed by secondary antibody, were used as controls. The peak shift was calculated as the difference in peak channels between cells stained with anti-CAR antibody and control cells with the highest fluorescein isothiocyanate signal Colony-formation assays P69, DU-145 and PC-3 cells were plated at a density of 1 Â 10 5 cells per 6-cm dish, and 1 day later were infected with Ad.5-mda-7, Ad.5/3-mda-7 or control virus (Ad.5-vec and Ad.5/3-vec). After 2 days, the cells were trypsinized and counted, and 300 cells were plated in 6-cm dishes. Colonies of 450 cells were scored after 12 days.
Preparation of whole-cell lysates and western blot analyses Preparation of whole-cell lysates and western blot analyses were performed as described previously. 27 The primary antibodies used were anti-BiP/GRP78 (Santa Cruz Biotechnology, Inc, Santa Cruz, CA), anti-Bcl-x L , anti-Bcl-2, PARP (poly(ADP-ribose) polymerase-1), p38 MAP (mitogenactivated protein) kinase, p-p38MAP kinase, ERK Enhanced therapeutic delivery of mda-7/IL-24 R Dash et al (extracellular signal-regulated kinase), phospho-ERK and p-eIF2a (phospho-eukaryotic initiation factor 2) (Cell Signaling Technology, Danvers, MA), anti-MDA-7/IL-24 (Gen Hunter Corporation, Nashville, TN), anti-EF1a (1:1000; mouse monoclonal; Upstate Biotechnology, Lake Placid, NY) and GRP94 (1:1000, Sigma, St Louis, MO).
Human prostate cancer xenografts in athymic nude mice DU-145 and PC-3 cells (3 Â 10 6 ) were injected subcutaneously in 100 ml of PBS in the left flank of male athymic nude mice (NCRnu/nu, 4 weeks of age, 20 g body weight). 27, 28 After establishment of visible tumors of B75 mm 3 , requiring approximately 8-10 days, intratumoral injections of different Ads were administered only to tumors on the left flank at a dose of 4.5 Â 10 8 p.f.u. (plaqueforming units) in 100 ml. The injections were administered 3 Â in the first week and then 2 Â a week for 2 more weeks for a total of seven injections. A minimum of five animals was used per experimental point. Tumor volume was measured twice weekly using a caliper and calculated using the formula: p/6 Â larger diameter Â (smaller diameter). 2 At the end of the experiment, animals were killed, and the tumors were removed and weighed.
Immunohistochemical staining
For immunohistochemical analysis, formalin-fixed and paraffin-embedded specimens of 3-4-mm thickness were sectioned. Sections were deparaffinized, re-hydrated and then quenched in 3% H 2 O 2 for 20 min. Sections were washed with PBS and blocked in PBS containing 1% bovine serum albumin for 20 min at 37 1C. Monoclonal anti-MDA-7/IL-24 (1:200), monoclonal anti-CD31 (1:200) (Dako Corporation, Carpenteria, CA) and Ki67 (1:50) (BD Pharmingen, San Diego, CA), were incubated for 3 h at room temperature and then washed 3 Â in PBS. Sections were incubated with an avidin-biotin-peroxidase complex (Vectastain Elite ABC Kit, Vector Laboratories, Burlingame, CA) and then washed 2 Â in PBS. Immunoreactivity was determined using diaminobenzidine as the final chromogen. Finally, sections were counterstained with Meyer's hematoxylin, dehydrated through a sequence of increasing concentrations of alcohol, cleared in xylene and mounted with epoxydic medium. During the immunohistochemical assay, proof slides were coupled with negative control slides on which the primary antibody was omitted. Sections were also processed for hematoxylin and eosin staining.
Statistical analysis
Statistical analysis was performed using one-way ANOVA (analysis of variance), followed by Fisher's protected least significant difference analysis. Po0.05 was considered significant. (Figure 1b) . Both Ad.5-vec (empty Ad.5 virus) and Ad.5/3-vec (empty Ad.5/3 virus) were used as controls. As a first test of comparative transduction efficiency, luciferase activity was analyzed after infection with Ad.5/3-Luc and Ad.5-Luc in P69, DU-145 and PC-3 cells (Figure 1c ). When PC-3 cells were infected with Ad.5/3-Luc, the level of luciferase activity with 50 or 100 p.f.u. per cell was markedly greater (*Po0.05) than that observed with Ad.5-Luc. The level of luciferase activities in DU-145 with Ad.5/3-Luc and Ad.5-Luc was comparable. In P69, there was an enhancement of luciferase activity (*Po0.05) with Ad.5/3-Luc when compared with Ad.5-Luc, although the magnitude of this enhancement was much less than that observed in PC-3 cells. These findings indicate that transduction efficiency in a low CAR tumor cell background was significantly enhanced by Ad.5/3 modification. Studies were next conducted to compare Ad.5/3 and Ad.5 expressing mda-7/IL-24 (Ad.5/3-mda-7 and Ad.5-mda-7, respectively). Infection of PC-3 cells with Ad.5-mda-7 was significantly less effective in generating MDA-7/IL-24 protein than Ad.5/3-mda-7 ( Figure 1d ). As a corollary to luciferase activity, infection with both Ad.5-mda-7 and Ad.5/3-mda-7 in DU-145 cells resulted in expression of equal amounts of MDA-7/IL24. The increased efficacy of Ad.5/3-mda-7 over Ad.5-mda-7 was also observed in P69 cells. It is to be noted that in low CAR containing colon cancer cells (RKO), infection with Ad.5/3-mda-7 also results in significantly high expression of MDA-7/IL-24 as compared with infection with Ad.5-mda-7 (Belal Azab et al., unpublished data). These findings confirm that Ad.5/3 chimerism results in enhanced transgene delivery in low CAR containing prostate cancer cells.
Ad.5/3-mda-7 shows enhanced cell killing in low CAR prostate cancer cells, without harming normal prostate cells The efficacy of Ad.5/3-mda-7 and Ad.5-mda-7 in inhibiting growth and inducing killing of prostate cancer cells was evaluated by cell viability (MTT) (Figure 2a ) and colony-formation assays ( Figure 2b) ; apoptosis assays were quantified by Annexin V staining, followed by flow cytometry (Figure 2c ) and trypan blue-dye exclusion test (Figure 2d ). Ad.5/3-mda-7 showed significantly (*Po 0.05) higher growth inhibition (Figures 2a and b) and cell We next analyzed the modulation of mda-7/IL-24 downstream genes and signals that confer its tumorsuppressing properties upon infection with Ad.5/3-mda-7 and Ad.5-mda-7 in PC-3 cells. mda-7/IL-24 induces an endoplasmic reticulum stress response (unfolded protein response), and we therefore checked the expression levels of endoplasmic reticulum stress markers. In PC-3 cells, the levels of BiP/GRP78, GRP94 and activation of p-eIF2a were significantly higher upon infection with Ad.5/3-mda-7 when compared with Ad.5-mda-7 ( Figure 3a) . The effect was more pronounced at a low m.o.i. of 50 p.f.u. per cell. Compared with Ad.5-mda-7, Ad.5/3-mda-7 efficiently induced apoptosis as evidenced by increased cleavage of PARP, downregulation of antiapoptotic proteins Bcl-2 and Bcl-x L , as well as activation of caspase 3/7 (Figures 3b and c) . Ad.5/ 3-mda-7, and not Ad.5-mda-7, efficiently activated the p38 MAPK, known to have a crucial role in mediating mda-7/ IL-24 effects, and inhibited the pro-survival ERK 42/44 activation (Figure 3d ). These findings further confirm that Ad.5/3 chimerism maintains the bona fide downstream effects exerted by mda-7/IL-24.
Ad.5/3-mda-7 eradicates primary and inhibits distant tumors generated by low CAR prostate cancer cells in nude mice To determine whether the in vitro enhanced activity of Ad.5/3-mda-7 vs Ad.5-mda-7 also translated to the in vivo situation, PC-3 and DU-145 tumors were established in the right and left flanks of athymic nude mice, respectively. After palpable tumors of B100 mm 3 developed, (Figure 4) . In PC-3 cells, a modest antitumor effect on the left-sided tumor was seen with Ad.5-mda-7 as evident by reduced tumor growth at week 5 (Figures 4a and b) . No effect was observed on right-sided tumors with Ad.5-mda-7. In contrast, Ad.5/ 3-mda-7 produced a dramatic effect in inhibiting the growth (*Po0.05) of the left-sided PC-3 tumors, which was evident by week 2 after initiating the therapeutic treatment protocol. A significant inhibition of growth of the right-sided uninjected PC-3 tumors was also observed on treatment with Ad.5/3-mda-7. In the DU-145 xenograft model, both Ad.5-mda-7 and Ad.5/3-mda-7 significantly inhibited left-sided tumor growth, which was evident by 2 weeks and also demonstrated comparable growth inhibition on right-sided tumors (Figures 4c  and d) . These findings provide definitive evidence for enhanced therapeutic efficacy of Ad.5/3-mda-7 vs Ad.5-mda-7 in prostate tumor cells with reduced CAR. These findings also highlight the potent 'bystander' anticancer activity of mda-7/IL-24 that results in the growth inhibition of right-sided noninjected tumors.
We next compared the efficacy of Ad.5/3-mda-7 and Ad.5-mda-7 in in vivo transgene delivery by staining for MDA-7/IL-24 protein, evaluating effects on angiogenesis by CD31 staining that detects microvessels. We studied the effects on cell proliferation by Ki-67 staining ( Figure 5 ). Tumors were harvested from the animals after three injections and were formalin fixed and paraffin embedded; sections from left tumors were subjected to immunohistochemistry for MDA-7/IL-24, Ki-67 and CD31. In PC-3 xenografts, infection with Ad.5/3-mda-7 generated significantly more MDA-7/IL-24 protein when compared with Ad.5-mda-7 that correlated with decreased expression of CD31 and Ki-67 (Figures 5a  and b) . In DU-145 xenografts, infection with both Ad.5-mda-7 and Ad.5/3-mda-7 showed significant expression of MDA-7/IL-24 and reduction in CD31 and Ki-67 staining (Figures 5c and d) . These findings indicate that in low CAR prostate cancer cells, Ad.5/3-mda-7 can efficiently generate MDA-7/IL-24 protein leading to inhibition of cell proliferation and angiogenesis. 
Discussion
Several attributes render the prostate gland an ideal candidate for gene therapy: the prostate gland is not vital for survival and is accessible by ultrasound; potential therapeutic genes can be injected directly into the primary tumor; tissue-specific promoters exist that can target therapeutic gene expression or viral replication uniquely in the prostate gland; and disease progression can be monitored by measuring prostate-specific antigen. [29] [30] [31] [32] [33] Moreover, as prostate cancer is a relatively slow-growing disease, it may be necessary to use repeated gene therapy approaches, with single or multiple genes, over the lifespan of the patient. 3 In these contexts, the use of replication defective Ads for administering therapeutic and/or cytotoxic genes in prostate tumor cells represents promising treatment options. [32] [33] Gene therapy, through either enforced expression or suppression of target gene overexpression, represents a potentially viable approach for the treatment of malignant and benign disorders. Ad is the best characterized of all viral-based delivery approaches, and Ad.5 is the most frequently used vector for therapeutic purposes. A limitation to the use of Ad.5 relates to infectivity by Ad.5, which is dependent on CAR levels in target cells. The infectivity of Ad on different prostate cancer cells has been previously analyzed. 34, 35 DU-145 and LNCaP have high CAR, whereas PC-3 has lower cell-surface CAR, which makes it relatively resistant to Ad infection. To circumvent this viral resistance, genetically engineered PC-3 cells have been generated by increasing 35% of CAR-positive cells to 86% CAR-positive cells. 35 When these high PC-3 CAR-transfected clones were infected with a recombinant Ad.5 CMV-p21 virus, there were Enhanced therapeutic delivery of mda-7/IL-24 R Dash et al elevated levels of p21 protein in virus-infected cells resulting in the accumulation of hypophosphorylated Rb, G1 arrest and apoptosis. This phenomenon was not observed in parental PC-3 cells or PC-3 cells transected by control vectors. 35 These studies highlight the importance of relative levels of CAR as a major determinant of Adbased gene therapy approaches. Strategies such as treatment with HDAC inhibitors have been shown to increase CAR levels in cancer cells resulting in increased sensitivity to TNF-related apoptosis inducing ligands. 36, 37 However, increasing the CAR level of cancer cells in patients is less tenable and practical as compared with modifying the Ad itself, so that it infects tumor cells in a CAR-independent manner.
To overcome the low infectivity limitation of Ad.5, multiple laboratories are attempting to solve the relative inefficiency of Ad.5 infection by modifying specific sequences within the virus capsid proteins that directly associate with CAR; that is, targeting strategies are being developed to enhance viral infectivity through CARindependent pathways. Several groups have modified the infective viral capsid 'knob' to bind to surface integrin proteins enhancing transformation (Arg-Gly-Asp (RGD) modification). [5] [6] [7] [8] [9] In addition, insertion into the knob of multiple lysine residues (pK 7 ) increases viral interaction with cells by electrostatic effects, and including portions of type 3 Ad in the viral capsid knob has also enhanced infectivity through CAR-independent pathways. [5] [6] [7] [8] [9] In this study, the potent tumor suppressor gene mda-7/IL-24 driven by a CMV promoter has been delivered by an Ad containing a chimeric fiber with the knob domain of human Ad.3 in the Ad.5 capsid (Ad.5/3), which redirects binding of the vector to the Ad.3 receptor (CD46 and CD80/CD86). Ad.5/3 uses group B receptors, CD46 and CD80/CD86, and displays enhanced transduction of malignant glioma cells having low CAR (U87MG and U373MG) compared with wild-type Ad.5. 38, 39 CD46 has also been shown to be overexpressed in some human neoplasms, 40 thereby protecting tumor cells from identification and destruction by the complement system, indicating a tumor-selective transduction ability by Ad.5/3. This concept was supported by the observation that Ad.5/3-Luc showed superior tumor-specific luciferase transgene expression when compared with Ad.5-Luc in normal human astrocytes. 39 Similarly, Ad.5/3-Luc also showed enhanced infectivity in ovarian cancer cells OV-4 Enhanced therapeutic delivery of mda-7/IL-24 R Dash et al and SKOV3, which display moderate or low levels of CAR, 41 as well as in renal cancer cells 42 and melanoma cells. 43 We presently extend these observations by showing that Ad.5/3 can effectively deliver a potent anticancer therapeutic, mda-7/IL-24, in low CAR prostate cancer cells; this has similar transduction efficiency as the wild-type Ad.5 in high CAR prostate cancer cells. Therefore, Ad.5/3 might be an effective tool for therapeutic delivery of a transgene into genetically diverse prostate tumors in vivo.
The unique and multifaceted anticancer properties of mda-7/IL-24, its profound activity in animal models and its success in a phase I clinical trial suggests that this gene might be ideal for gene therapy in cancer. [16] [17] [18] To engender an optimum therapeutic response using mda-7/IL-24, defining ways of ensuring efficient delivery of the molecule to the target cancer tissue would be helpful. By permitting virus entry in a CAR-independent manner, Ad.5/3 removes one important roadblock to effective in vivo delivery of therapeutic viruses. However, with systemic administration, there still are other paramount issues preventing optimum use of Ad for systemic therapy, including squelching of Ad by the liver, immune system-mediated clearance of circulating Ad and development of anti-Ad antibodies precluding multiple administrations. These hurdles can also be overcome by genetically modifying the Ad capsid to decrease immunogenicity, 44 modifying the Ad to decrease targeting to the liver 44 and/or by encapsulating the Ad with a ultrasound contrast reagent (microbubbles) and releasing the Ad in the tumor milieu by ultrasound-targeted microbubble destruction. 45 Our future studies are designed to evaluate microbubble-targeted Ad.5/3-mda-7 in a transgenic mouse model of prostate cancer to elicit the full repertoire of antitumor effects of mda-7/IL-24 in an immunocompetent animal. Previous studies have documented that human mda-7/IL-24 efficiently stimulates the mouse immune system; 46 thus, a transgenic mouse prostate cancer model, such as the Hi-Myc mouse that closely mimics human prostate cancer, 47 might be an ideal way to evaluate therapeutic efficiency, toxicity and biodistribution of Ad.5/3-mda-7. Our current and future studies will provide baseline information to ultimately translate Ad.5/3-mda-7 into the clinic for gene therapy of cancer with the aim of developing an effective therapeutic for prostate and other cancers.
